Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 11/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15772531 | 0.82 | MTNR1A (0.52) | HTR1BMCHR1HTR1DCNR1CNR2 | |
| SCHEMBL7835596 | 0.82 | CYP2A6 (0.50) | HTR1BMCHR1HTR1DCNR1CNR2 | |
| SCHEMBL15473247 | 0.82 | HTR1B (0.49) | HTR1BMCHR1HTR1DCNR1CNR2 | |
| SCHEMBL7836096 | 0.81 | CYP1A2 (0.46) | HTR1BSLC6A4 | |
| Ammonia Solution, Strong SCHEMBL27919268 | 0.81 | CYP2A6 (0.49) | HTR1BMCHR1HTR1DCNR1CNR2 | |
| SCHEMBL15473235 | 0.79 | MTNR1A (0.51) | HTR1BMCHR1HTR1DCNR1CNR2 | |
| SCHEMBL7823164 | 0.79 | HTR1B (0.51) | HTR1BMCHR1HTR1DCNR1CNR2 | |
| SCHEMBL30209610 | 0.79 | HTR1B (0.70) | HTR1BHTR1DCNR1CNR2SLC6A4 | |
| SCHEMBL2116954 | 0.79 | HTR1B (0.70) | HTR1BHTR1DCNR1CNR2SLC6A4 | |
| SCHEMBL15345837 | 0.78 | CSNK2A1 (0.55) | HTR1BMCHR1HTR1DCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| CN-1066729-C | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-06-06 | — | — | CN | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| CN-1157288-A | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |